ArticleGynecologic oncology reports2026

Real-world outcomes after Mirvetuximab Soravtansine treatment for recurrent ovarian Cancer: Results from a university setting.

Anna V Jones et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.